Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CD28/4-1BB CD123 CAR T cells in blastic plasmacytoid dendritic cell neoplasm
Elodie Bôle‐Richard, Maxime Fredon, Sabeha Biichlé, et al.
Leukemia (2020) Vol. 34, Iss. 12, pp. 3228-3241
Closed Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 61
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
Nadia El Khawanky, Amy Hughes, Wenbo Yu, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 78
Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies
Zhengzheng Zhang, Tian Wang, Xiaofeng Wang, et al.
Pharmacological Research (2021) Vol. 175, pp. 106036-106036
Open Access | Times Cited: 72
Inhibitory CARs fail to protect from immediate T cell cytotoxicity
Maximilian A. Funk, Gerwin Heller, Petra Waidhofer‐Söllner, et al.
Molecular Therapy (2024) Vol. 32, Iss. 4, pp. 982-999
Open Access | Times Cited: 13
Adoptive Cell Therapy in Hepatocellular Carcinoma: Biological Rationale and First Results in Early Phase Clinical Trials
Philippe Rochigneux, Brice Chanez, Bernadette de Rauglaudre, et al.
Cancers (2021) Vol. 13, Iss. 2, pp. 271-271
Open Access | Times Cited: 54
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Matteo Libero Baroni, Diego Sánchez‐Martínez, Francisco Gutiérrez Agüera, et al.
Journal for ImmunoTherapy of Cancer (2020) Vol. 8, Iss. 1, pp. e000845-e000845
Open Access | Times Cited: 53
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
Tianyu Cai, Agnès Gouble, Kathryn L. Black, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 32
Plasmacytoid dendritic cell neoplasms
Yoo Jin Lee, Youjin Kim, Sang Hyuk Park, et al.
Blood Research (2023) Vol. 58, Iss. S1, pp. S90-S95
Open Access | Times Cited: 19
Central nervous system involvement in blastic plasmacytoid dendritic cell neoplasm
Naveen Pemmaraju, Nathaniel R. Wilson, Joseph D. Khoury, et al.
Blood (2021) Vol. 138, Iss. 15, pp. 1373-1377
Open Access | Times Cited: 41
First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G
François Anna, Elodie Bôle‐Richard, Joël LeMaoult, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 3, pp. e001998-e001998
Open Access | Times Cited: 37
The Implementation of TNFRSF Co-Stimulatory Domains in CAR-T Cells for Optimal Functional Activity
Yuan He, Martijn Vlaming, Tom van Meerten, et al.
Cancers (2022) Vol. 14, Iss. 2, pp. 299-299
Open Access | Times Cited: 25
Recent Advances in Material Technology for Leukemia Treatments
Feng Li, Huaiji Wang, Tong Ye, et al.
Advanced Materials (2024) Vol. 36, Iss. 26
Closed Access | Times Cited: 6
Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123
Serena Zanotta, Domenico Galati
(2024)
Open Access | Times Cited: 5
Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy
Nathaniel R. Wilson, Marina Konopleva, Joseph D. Khoury, et al.
Clinical Lymphoma Myeloma & Leukemia (2021) Vol. 21, Iss. 11, pp. 734-740
Closed Access | Times Cited: 29
Umbilical Cord Blood as a Source of Less Differentiated T Cells to Produce CD123 CAR-T Cells
Blandine Caël, Jeanne Galaine, Isabelle Bardey, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3168-3168
Open Access | Times Cited: 20
Selective Cytotoxicity of Single and Dual Anti-CD19 and Anti-CD138 Chimeric Antigen Receptor-Natural Killer Cells against Hematologic Malignancies
Sudjit Luanpitpong, Jirarat Poohadsuan, Phatchanat Klaihmon, et al.
Journal of Immunology Research (2021) Vol. 2021, pp. 1-16
Open Access | Times Cited: 26
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics
Ijele Adimora, Nathaniel R. Wilson, Naveen Pemmaraju
Cancer (2022) Vol. 128, Iss. 16, pp. 3019-3026
Closed Access | Times Cited: 17
Optimal Chimeric Antigen Receptor (CAR)-mRNA for Transient CAR T Cell Generation
Reni Kitte, Robert Serfling, Ulrich Blache, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 965-965
Open Access
Immunotherapies Targeting CD123 and CD303: A New Frontier in Treating Blastic Plasmacytoid Dendritic Cell Neoplasm
Domenico Galati, Serena Zanotta, Francesca Florio, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 6, pp. 2732-2732
Open Access
Characterization of the aryl hydrocarbon receptor as a potential candidate to improve cancer T cell therapies
Valentine De Castro, Oumaïma Abdellaoui, Barbara Dehecq, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 7
Open Access
Smart nanomaterials for multimodal theranostics and tissue regeneration
Hyun Lee, Kyoung Sub Kim, Iman Zare, et al.
Coordination Chemistry Reviews (2025) Vol. 541, pp. 216801-216801
Closed Access
Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123
Serena Zanotta, Domenico Galati, Rosaria De Filippi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 3, pp. 1454-1454
Open Access | Times Cited: 3
Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches
Wei Cheng, Tiantian Yu, Aiping Tang, et al.
Current Medical Science (2021) Vol. 41, Iss. 3, pp. 405-419
Open Access | Times Cited: 18
Conventional Therapeutics in BPDCN Patients—Do They Still Have a Place in the Era of Targeted Therapies?
Margaux Poussard, Fanny Angelot‐Delettre, Éric Deconinck
Cancers (2022) Vol. 14, Iss. 15, pp. 3767-3767
Open Access | Times Cited: 12
Diagnosis, treatment, and genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A review
Yemin Wang, Xiao Li, Lili Yin, et al.
Medicine (2023) Vol. 102, Iss. 7, pp. e32904-e32904
Open Access | Times Cited: 7
Page 1 - Next Page

Scroll to top